ACUS — Acusphere Share Price
Last Trade - 00:00- $0.05m
- $10.02m
- $2.68m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2004 | 2005 | 2006 | 2007 | 2008 | 2009E | 2010E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.71 | 3.43 | 1.78 | 2.67 | 2.68 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acusphere, Inc. is a specialty pharmaceutical company. The Company is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The Company's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The Company has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Directors
- Martyn Greenacre CHM (78)
- Mark Leuchtenberger (52)
- Sherri Oberg VCH
- William Ramage (50)
- Garen Bohlin (72)
- Sandra Fenwick (69)
- Derek Lemke-von Ammon (52)
- Last Annual
- December 31st, 2008
- Last Interim
- December 31st, 2008
- Incorporated
- July 12th, 1993
- Public Since
- October 8th, 2003
- No. of Employees
- 118
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,950,677
- Address
- 99 Hayden Ave Ste 385, LEXINGTON, 02421-7998
- Web
- http://www.acusphere.com
- Phone
- +1 6176488800
- Auditors
- Deloitte & Touche LLP
Similar to ACUS
AIDA PHARMACEUTICALS ORD
Pink Sheets on Nasdaq
ANBC ORD
Pink Sheets on Nasdaq
AOXING PHARMACEUTICAL ORD
Pink Sheets on Nasdaq
EMERGENT HEALTH ORD
Pink Sheets on Nasdaq
INTEGRATED PHARMACEUTICALS ORD
Pink Sheets on Nasdaq
FAQ
As of Today at 19:56 UTC, shares in Acusphere are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Acusphere last closed at $0.01 and the price had moved by -60% over the past 365 days. In terms of relative price strength the Acusphere share price has underperformed the S&P500 Index by -69.06% over the past year.
There is no consensus recommendation for this security.
Acusphere does not currently pay a dividend.
Acusphere does not currently pay a dividend.
Acusphere does not currently pay a dividend.
To buy shares in Acusphere you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Acusphere had a market capitalisation of $0.05m.
Here are the trading details for Acusphere:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ACUS
Based on an overall assessment of its quality, value and momentum Acusphere is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acusphere. Over the past six months, its share price has underperformed the S&P500 Index by -62.21%.
As of the last closing price of $0.01, shares in Acusphere were trading -62.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acusphere.
Acusphere's management team is headed by:
- Martyn Greenacre - CHM
- Mark Leuchtenberger -
- Sherri Oberg - VCH
- William Ramage -
- Garen Bohlin -
- Sandra Fenwick -
- Derek Lemke-von Ammon -
We do not have data on Acusphere's shareholders